(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
IDF begins destroying homes used by Hezbollah as forces move deeper into southern Lebanon - 2How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- 3Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
- 4Germany paves the way for tighter EU asylum rules
- 5Select Your Go-To Bluetooth Earphones
- NASA releases new ‘Earthset’ and eclipse images taken during historic flyby of the moon
- The 10 Most Noteworthy Games in History
- 'Wow!' The eye surgery marathon that restored sight for some South Africans
- Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- A coup too far: Why Benin's rebel soldiers failed where others in the region succeeded
- The Secret Destinations Amex Says Will Be More Popular Than Bali by 2026
- Most loved Occasion Dish: What Makes Your Merry Table?
- 5 Wellbeing Applications Assist You With remaining Fit
- Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
